Lauren E. Merz

Nov 2, 2024 | sciencedirect.com | Kevin J Barnum |Kenneth Bauer |Lauren E. Merz |Annemarie E. Fogerty

Universal disclosures for H.A.S.: consultancy (Agios, Sobi, Argenx, Pharmacosmos, Novartis, Amgen, Alnylam, and Alpine) and research funding (Agios, Sobi, Amgen, Vaderis, and Novartis). H.A.S. is funded by the ( ). As the sole author, H.A.S. is responsible for all aspects of the manuscript, from conception to completion. © 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.

Sep 11, 2024 | jamanetwork.com | Stephen P Hibbs |Laura Aiken |NHS Blood |Lauren E. Merz

Key PointsQuestion  Do cancer clinical trials and anticancer regimens restrict participation of individuals with Duffy null–associated absolute neutrophil counts (DANCs) by setting exclusions and dose modifications within their neutrophil reference range?